Gerald Proehl
Angel Investor
San Diego, United States
Gerald Proehl is a seed investor in San Diego focused on Medical and Therapeutics. Gerry Proehl is the former President and CEO of Santarus, Inc. where he led the sale of that company to Salix in early 2014 for $2.6 billion. Prior to Santarus, Proehl was with Hoechst Marion Roussel for 14 years, where he served in various capacities, including Vice President of Global Marketing. While at Hoechst, he was responsible formarketing products in multiple therapeutic areas, including the central nervous system. Proehl holds a BS in education from the State University of New York at Cortland, an MA in exercise physiology from Wake Forest University, and an MBA from Rockhurst College.Chair of the Nominating and Governance Committee, Member of the Compensation Committee
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Gerald Proehl invests in
Stages Gerald Proehl invests in
Countries Gerald Proehl invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 2 (67%)
- Therapeutics 2 (67%)
- Biotechnology 2 (67%)
- Biopharma 1 (33%)
- Health Care 1 (33%)
Stage
- Seed 1 (33%)
- Series A 1 (33%)
- Post-IPO Equity 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Clarify Medical is innovating a well-established treatment, UVB therapy, to become easier, more convenient, more empowering, and more connected for psoriasis, eczema and vitiligo patients. The company also focused on developing innovative technology, products, and services that improve care for people with chronic skin conditions.Clarify Medicalindicated for the localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of UVB light therapy, helping to ensure that patients receive the proper doses recommended by the American Academy of Dermatology and Vitiligo Working Group. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress, and satisfaction. | $1.4M / Series A / Dec 03, 2015 | ||
| Dermata is a development-stage biotechnology company that focuses on making major advancements in the treatment of serious diseases treated by dermatologists. Its business strategy is to identify and develop innovative products that move into clinical trials to demonstrate efficacy and safety in a variety of diseases. They currently exploring theuse of a unique botanical product with multiple proposed mechanisms of action in order to treat acne.It was founded in 2014 and headquartered in Encinitas, California. | $4.1M / Post-IPO Equity | ||
| Clarify Medical is innovating a well-established treatment, UVB therapy, to become easier, more convenient, more empowering, and more connected for psoriasis, eczema and vitiligo patients. The company also focused on developing innovative technology, products, and services that improve care for people with chronic skin conditions.Clarify Medicalindicated for the localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of UVB light therapy, helping to ensure that patients receive the proper doses recommended by the American Academy of Dermatology and Vitiligo Working Group. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress, and satisfaction. | Seed |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Gerald Proehl invest in?
Gerald Proehl invests primarily in Medical, Therapeutics and Biotechnology startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Gerald Proehl?
Public channels for Gerald Proehl include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Gerald Proehl last invest?
The most recent investment recorded for Gerald Proehl closed in Dec 2015. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
